Interleukin-17 family (IL-17 family) is a pro-inflammatory cystine node cytokine family. After binding to the receptor, IL-17 can activate several signal cascades, leading to the induction of chemokines. As chemokines, these chemokines recruit immune cells to inflammatory sites. Specifically, IL-17 promotes inflammation and cooperates with tumor necrosis factors and interleukin-1. Besides, the IL-17 cytokine family has many immunomodulatory functions. The most significant role of IL-17 is that it participates in inducing and mediating proinflammatory responses. Moreover, IL-17A promotes inflammation by inducing various pro-inflammatory cytokines and chemokines, recruiting concentrated granulocytes, enhancing antibody production, and activating T cells.
Furthermore, IL-17A is one of the six members of the known IL-17 cytokine family. Meanwhile, IL-17A IL-17RA is relevant to the immune response to infectious pathogens and the pathogenesis of inflammatory autoimmune diseases. Nonetheless, IL-17A and IL-17F have the highest structural homology in the IL-17 cytokine family, so they have very similar biological functions. The T cell subsets producing IL-17A are attractive targets for drug stem preparation. In addition, the expression of IL-17A in synovial tissue and body fluids of patients with psoriasis arthritis can recruit myelogenous inhibitory cells (MDSC) to inhibit anti-tumor immunity. Nonetheless, the T cell subsets producing IL-17A are attractive targets for drug stem preparation. Here, we will introduce a potent antibody, Secukinumab.
Secukinumab (AIN457) is a Human Monoclonal Antibody Targeted against IL-17A.
First of all, Secukinumab (AIN457) is a high affinity and human monoclonal antibody targeted against IL-17A. Obviously, Secukinumab is the first-in-class anti-IL-17 agent. Obviously, Secukinumab has the potential for the research of plaque psoriasis, ankylosing spondylitis and psoriatic arthritis.
In the second place, Secukinumab is a fully human monoclonal antibody that selectively binds to and neutralizes interleukin-17A. Interestingly, Secukinumab with 1-100 nM inhibits IL17A and IL17A/TNF an-induced increase in protein levels of IL6 in human astrocytes.
Last but not the least, IL-17 is usually associated with allergic reactions. In addition, the expression of IL-17A in synovial tissue and body fluids with psoriasis arthritis can recruit myelogenous inhibitory cells (MDSC) to inhibit anti-tumor immunity.
All in all, Secukinumab is a high affinity and human monoclonal antibody targeted against IL-17A.